A study was conducted in Nova Scotia to assess the risks associated with aprotinin, which the authors hypothesized is associated with higher risk of adverse outcomes than tranexamic acid, according to MDLinx.
The retrospective study looked at 3,340 patients with cardiac surgery and in-hospital outcomes of postoperative mortality, new acute renal failure and perioperative blood transfusion.
Patients who received aprotinin were more often elderly and female. In-hospital mortality was significantly higher in the aprotinin group compared to the TXA group, up 5 percent. The ICU stay was also significantly increased in the aprotinin group, up 8.3 percent.
More Articles on Anesthesia:
Mazzetti, Anesthetic Gas Reclamation Strive to Recapture Anesthetic Gas in Hospitals
Congress Examines Anesthesiologist Exemption to Meaningful Use
Hurricane Sandy Exacerbates Propofol Shortage
The retrospective study looked at 3,340 patients with cardiac surgery and in-hospital outcomes of postoperative mortality, new acute renal failure and perioperative blood transfusion.
Patients who received aprotinin were more often elderly and female. In-hospital mortality was significantly higher in the aprotinin group compared to the TXA group, up 5 percent. The ICU stay was also significantly increased in the aprotinin group, up 8.3 percent.
More Articles on Anesthesia:
Mazzetti, Anesthetic Gas Reclamation Strive to Recapture Anesthetic Gas in Hospitals
Congress Examines Anesthesiologist Exemption to Meaningful Use
Hurricane Sandy Exacerbates Propofol Shortage